Invest in Neurocarrus
Treating Neurodegenerative Disease and Pain Without Addiction
Highlights
1
Drug candidate N-001 provides relief from acute pain in animals caused by inflammation or surgery.
2
Neurocarrus has built a pipeline of drugs using the APOLLO targeting and delivery system.
3
N-001, NL-17, N-19a treat acute, migraine and chronic pain by sensory neuron targeting.
4
The APOLLO drugs use a unique manufacturing process to discourage competitors.
Featured Investor
Invested $17,000
Invested $15,000 this round & $2,000 previously
“I believe that Neurocarrus has the potential to revolutionize pain management. Paul and his team have created an incredibly clever drug the produces long lasting pain relief with no side effects or possibility of addiction. Neurocarrus’s N-001 has the potential to become the new standard of care for pain management, improving patient outcomes while eliminating the risk of opioid addiction. With backing from the National Institutes of Health, Neurocarrus is well on their way to changing the wo...”
Our Team
Co-founder/CEO
30+ years in cell engineering and microbiology, focused on protein drug development. Paul is full time CEO of Neurocarrus in Monterey, California. He is a serial inventor and was an endowed university professor.
Derek AllenResearch Scientist
Ph.D. focused on protein drug development with emphasis on protein synthesis and purification. Also specialized in bioassays and potency studies.
Jianguo Cheng, MD, Ph.DBoard Member
Professor and Director, Cleveland Clinic; Past President, American Academy of Pain Medicine. Highly active in research and pain medicine and strongly supported by NIH. Also an active editor in top pain journals.
Publications:
Neurocarrus top scientific publications:
Animal efficacy and safety studies
Targeting, mechanism, and efficacy studies
Drug design and engineering studies